Formulation Development
Minoryx & Neuraxpharm Announce Strategic Alliance to Provide New Therapy for Rare CNS Disease
The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD)….
Evonik Wins Pharma Award for Polymer-Based Technology for mRNA Delivery
Evonik Health Care has won the prestigious CPHI Excellence in Pharma Award in the category Packaging and Drug Delivery. The winning innovation is a new…
Immutep Granted New Patents for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
Immutep Limited recently announced the grant of two new patents (Nos. 7160345 and 10-2441425) titled Combined Preparations for the Treatment of Cancer by the Japanese Patent…
Ocuphire Pharma Enters Global License Agreement for Development & Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia & Night Vision Disturbances
Ocuphire Pharma, Inc. recently announced it has concluded an exclusive license agreement with FamyGen Life Sciences, Inc. for the development and commercialization of Nyxol across…
Insilico Medicine Signs Strategic Research Collaboration With Sanofi Worth up to $1.2 Billion
Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single to low double-digit royalties….
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE (setmelanotide) in Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced that previously disclosed results from a Phase 3 clinical trial that evaluated IMCIVREE (setmelanotide), an MC4R agonist, in patients with…
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Achieve Life Sciences, Inc. recently announced target enrollment has been reached in the Phase 2 ORCA-V1 clinical trial. ORCA-V1 is evaluating the efficacy and safety…
GHO Capital & The Vistria Group to Acquire Alcami From Madison Dearborn Partners & Ampersand Capital Partners
Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact, recently….
Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors
Fate Therapeutics, Inc. recently announced that ONO Pharmaceutical Co., Ltd. (ONO) has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) T-cell…
Actym Therapeutics Reports Preclinical Data Demonstrating Ability to Generate Anti-Tumor Immunity
Actym Therapeutics recently announced an abstract highlighting detailed in vivo and in vitro preclinical data of its lead candidate, ACTM-838, was accepted for presentation at the Society…
NovaQuest Private Equity Announces Investment In Bend Bioscience to Broaden CoreRx Offering
Bend Bioscience and QHP Capital (the management company for NovaQuest Private Equity) have recently announced plans to invest in a new operation in Bend, OR,…
Exelixis & Catalent Enter New License Agreement for Three Antibody-Drug Conjugate Programs With the Potential to Accelerate Exelixis’ Biologics Pipeline
Exelixis, Inc. and Catalent, Inc. recently announced a new license agreement under which Catalent’s Redwood Bioscience subsidiary will grant Exelixis an exclusive license to three target programs with….
Servier & OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome
Servier and OSE Immunotherapeutics SA recently announced the completion of patient enrollment in the Phase 2a clinical trial evaluating the efficacy and safety of monoclonal…
APEIRON Respiratory Therapies Announces Positive Results From Phase I Trial of Inhaled APN01
APEIRON Respiratory Therapies GmbH recently announced positive final results from a Phase 1 clinical trial of inhaled APN01 (alunacedase alfa), a soluble recombinant version of…
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
Inozyme Pharma, Inc. recently announced the first self-administration of INZ-701 in the open-label Phase 2 extension portion of the ongoing Phase 1/2 clinical trial of INZ-701…
TFF Pharmaceuticals Announces Collaboration With Aptar Pharma to Explore & Develop Intranasal Delivery of Dry Powder Vaccines & Dry Powder Therapeutics
TFF Pharmaceuticals, Inc. recently announced a collaboration with Aptar Pharma aimed at developing and testing the administration of dry powder vaccines utilizing….
Jounce Therapeutics Earns Clinical Milestone Payment Under Exclusive License Agreement With Gilead Sciences
Jounce Therapeutics, Inc. recently announced earning a $15-million clinical milestone payment from Gilead Sciences, Inc. under the exclusive license agreement for….
Acumen Publishes Phase 1 Trial Design & Clinical Development Plan for an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced it published its development rationale and clinical development plan for ACU193, the first clinical-stage monoclonal antibody that selectively targets toxic soluble….
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. recently announced that setmelanotide received Breakthrough Therapy Designation from the US FDA for the treatment of hypothalamic obesity. The FDA's Breakthrough Therapy…
Processa Successfully Identifies Next-Generation Capecitabine Dosage Regimens for Phase 2B Trial
Processa Pharmaceuticals, Inc. recently announced positive results from its ongoing Next-Generation Capecitabine (NGC) Phase 1B trial. The data collected has allowed Processa to estimate the…
